GPT and Cirrhosis: The EASL CPG published in 2017 recommend antiviral treatment for 1) all patients with HBeAg-positive or -negative CHB; 2) patients with cirrhosis and detectable HBV DNA; 3) patients with HBV DNA > 20,000 IU/ml and ALT > 2 x ULN; and 4) patients with HBeAg-positive chronic infection older than 30 years [1].